After jointly developing JF-17 fighter jets, Pakistan now formally inducts advanced Chinese tank

Pakistan's Army Chief General Qamar Javed Bajwa (2R) witnesses the commissioning of an advanced Chinese tank into the army’s strike formation in Gujranwala, Pakistan, on October 12, 2021. (Photo courtesy: ISPR)
Short Url
Updated 13 October 2021
Follow

After jointly developing JF-17 fighter jets, Pakistan now formally inducts advanced Chinese tank

  • General Qamar Javed Bajwa witnessed the induction of the VT-4 tank into the army’s strike formation
  • Pakistan and China inked a defense pact in 2020 after US and India signed military agreement

ISLAMABAD: Pakistan’s army chief General Qamar Javed Bajwa applauded his country’s strategic partnership with China after witnessing the commissioning of an advanced Chinese tank into the army’s strike formation in Gujranwala city on Tuesday.
Pakistan and China have maintained strong diplomatic and military cooperation with each other.
The two countries signed a defense pact in December 2020, only a few months after the United States and India reached the Basic Exchange and Cooperation Agreement for Geo-Spatial Cooperation.
After jointly developing JF-17 fighter jet with China, Pakistan formally inducted VT-4 Tank on Tuesday, said the military’s media wing, ISPR, in an official statement.
“VT-4 Tank is another symbol of [the] Pakistan-China strategic cooperation and defense collaboration,” the army chief said at the occasion. “Its induction will boost strike capabilities of our formations.”
According to the ISPR statement, the Chinese tank “is a robust war fighting machine” with “advanced armor protection, high maneuverability and exceptional firepower.”
“The fast-changing dynamics of warfare demand highest degree of professionalism and rigorous training with due focus on harnessing sophisticated technologies,” he added.
General Bajwa maintained that a continuous up-gradation of conventional capabilities was imperative to maintain “qualitative edge over adversary and deter aggression.”
He also witnessed the Dynamic Integrated Training Simulator for VT-4 Tank.


Pakistan opposition continues sit-in outside parliament over ex-PM Khan’s eye treatment

Updated 5 sec ago
Follow

Pakistan opposition continues sit-in outside parliament over ex-PM Khan’s eye treatment

  • Opposition leader says the protest will continue until Imran Khan, currently at Adiala prison, is admitted to Shifa Hospital
  • The government says Khan’s medical report will be compiled again, promising no negligence in the matter under judicial oversight

ISLAMABAD: Pakistan’s opposition alliance is continuing its sit-in outside the Parliament House in Islamabad for the second day on Saturday, seeking shifting of jailed former prime minister Imran Khan to a private hospital for treatment of his worsening eye condition.

The protest follows a rare prison visit earlier this week by Barrister Salman Safdar, appointed as amicus curiae by the Supreme Court to assess Khan’s health and living conditions at Rawalpindi’s Adiala jail. In his report, Safdar highlighted “seriousness” of Khan’s ocular condition and recommended an independent examination.

On Friday evening, opposition members gathered outside the parliament building in Islamabad to stage a sit-in, with the police locking its gates and cordoning off surrounding roads to prevent protesters from gathering in front of the building, witnesses and opposition leaders said.

Mehmood Khan Achakzai, the head of the Tehreek-e-Tahafuz-e-Ayeen-e-Pakistan opposition alliance, criticized the authorities for the measures to prevent opposition members from reaching the sit-in venue in Islamabad.

“We are not the ones who make threats, but if you continue with this attitude, after two or three days every roundabout in Pakistan will be closed,” Achakzai said on X late Friday. “Then we will not even be able to handle the people.”

In an earlier post on X, the alliance said its leadership would continue the sit-in “until Imran Khan is admitted to Al-Shifa Hospital.”

“We have staged a sit-in for the earliest medical check-up of Imran Khan, which would take just ten minutes,” Achakzai told reporters on Friday evening. “If it is conducted, we will end our protest.”

According to a Feb. 6 medical report from the Pakistan Institute of Medical Sciences (PIMS) cited in Safdar’s filing, Khan was diagnosed with “right central retinal vein occlusion” after reporting reduced vision in his right eye. He underwent an intravitreal injection at PIMS and was discharged with follow-up advice.

In his interaction with Safdar, Khan said he had suffered “rapid and substantial loss of vision over the preceding three months” and claimed his complaints had not been addressed promptly in custody. He further said he had been left with “only 15 percent vision in his right eye.”

Safdar’s report noted that the 73-year-old former premier appeared “visibly perturbed and deeply distressed” over the loss of vision, though it also recorded that he expressed satisfaction with his safety, basic amenities and food provisions in prison.

Responding to the controversy, Parliamentary Affairs Minister Tariq Fazal Chaudhry rejected PTI’s claims that Khan had been suffering from an eye issue since October last year, noting that the ex-premier was visited by his sister on Dec. 2 but she did not mention the medical issue.

“Medical report will be compiled again, the chief justice of the Supreme Court is himself monitoring this case,” he said. “Wherever it will be requested, Imran Khan’s eye will be examined at.”

Chaudhry vowed there would be no negligence.

Khan has been in custody since August 2023 in connection with multiple cases that he and his party describe as politically motivated. The government denies the allegation.

Concerns over his health resurfaced after authorities confirmed he had briefly been taken from prison to a hospital in Islamabad for an eye procedure. While the government said his condition was stable, Khan’s family and PTI leaders alleged they were not informed in advance and that he was being denied timely and independent medical access.